Aegon's H1 2026 result is most useful to US life and retirement brokers not as a financial scorecard but as a read on what Transamerica - the US operating business and the company's explicit future - is doing at the distribution level. Individual life sales grew 54% compared with the first half of 2025. World Financial Group, Transamerica's affiliated agent network, surpassed 100,000 licensed agents. Retirement Plans maintained good commercial momentum in written sales. Those are the numbers that tell brokers where Transamerica is investing and where it expects to grow.
The group headline: operating result of EUR 804 million in H1 2026, up 9% from EUR 737 million in H1 2025. Net result of EUR 608 million, broadly flat versus EUR 606 million a year earlier. Operating capital generation after holding funding and operating expenses grew 27% to EUR 416 million. The interim dividend was raised 11% to EUR 0.21 per share. Aegon CEO Lard Friese confirmed the group is on track to meet or exceed all Group financial ambitions for 2026.
Transamerica's 54% increase in individual life sales is not a soft-market volume play - it is concentrated in a specific product category: the instant decision market. Transamerica has been building its digital underwriting capability to offer same-sitting coverage decisions on eligible life applications, removing the medical underwriting delays that historically made life insurance a friction-heavy purchase for the middle-income families the company targets.
For life brokers distributing Transamerica products, this matters in two ways. First, it validates a product proposition that is actively expanding the addressable market - clients who previously deferred life purchase decisions because of the underwriting process are now converting. Second, it signals where Transamerica is deploying its technology investment. The capability being built for instant decision life is the same infrastructure that will be applied to expanding digital distribution across Transamerica's broader Protection Solutions range, which includes term life, whole life, universal life, indexed universal life, and living benefit riders covering long-term care costs.
WFG surpassing 100,000 agents is the distribution headline. The prior milestone was approximately 95,000 agents at the end of 2025, where the network also delivered a record 30% increase in individual new life sales for the full year, according to Aegon's H2 2025 results announcement. For independent brokers not affiliated with WFG, the practical implication is a Transamerica agent network that is covering the middle-income market more aggressively than at any recent point in its history.
Transamerica's Retirement Plans business maintained good commercial momentum in written sales in H1 2026. Transamerica is a significant provider of defined contribution plan recordkeeping, covering 401(k), 403(b), 457, profit-sharing, money purchase, multiple employer plans, and pooled employer plans, alongside ancillary products including the General Account Stable Value product and Individual Retirement Accounts.
The context for "good commercial momentum" is the competitive field Transamerica operates in: the defined contribution recordkeeping market has consolidated significantly, with Empower, Fidelity, Vanguard, and Principal commanding the largest share of plans by assets. Transamerica's strategic positioning is explicitly in pooled employer plans and the small-to-mid-market - a segment where Aegon's 2025 Capital Markets Day identified expanding penetration and deepening the ancillary product range as two of the company's near-term growth priorities. For retirement plan brokers advising plan sponsors in that market, Transamerica is a carrier investing in the precise segment where broker relationships are most consequential. Large plan sponsors typically have direct carrier access; small and mid-market plan sponsors typically need broker guidance. That alignment is worth understanding when evaluating the strength of Transamerica's commitment to the intermediated channel.
Aegon selected New York City as the future location of its head office and announced leadership changes in H1 2026. An Extraordinary General Meeting is targeted for October 8, 2026 to seek shareholder approval for the US domiciliation. Following completion, which Aegon aims to conclude by January 1, 2028, the holding company will be renamed Transamerica Inc.
For US brokers, the redomiciliation is more than structural housekeeping. A company physically relocating its headquarters to New York City, renaming itself after its US business, and seeking US-aligned governance is making an irreversible statement about where its product development priorities, regulatory relationships, and distribution investment will be concentrated. That is a long-term positive signal for brokers whose relationships are built around Transamerica products - the parent company's strategic centre of gravity is moving to them, not away.
Aegon also announced on August 20 that CFO Duncan Russell will step down and leave the company in April 2027, in connection with the planned US relocation. A successor search has been initiated. Russell said he would remain "fully committed to supporting an orderly transition" and Friese credited him with "strengthening our financial foundations and positioning the company for long-term success." The departure is structured, with a defined timeline and a search underway - this is managed succession, not an unexpected exit, and the April 2027 timeline gives significant runway for transition.
Aegon agreed in April 2026 to sell Aegon UK to Standard Life for total consideration of GBP 2.0 billion, comprising a 15.3% stake in Standard Life and GBP 750 million in cash. The deal is expected to close around year-end, subject to regulatory approvals. As a result of Aegon's accounting policies, Aegon UK no longer contributes to the group's operating result or operating capital generation from H1 2026 - which explains why the free cash flow comparison of EUR 392 million versus EUR 442 million in H1 2025 looks lower despite strong underlying performance. The UK exclusion accounts for the difference.
Group operating result EUR 804 million (+9%), operating capital generation EUR 416 million (+27%), free cash flow EUR 392 million. Cash Capital at Holding of EUR 1.7 billion. H2 2026 share buyback increased by EUR 150 million to a total of EUR 350 million. Valuation equity per share EUR 9.42, up 4% in the reporting period. Q3 results are due November 2026.
